Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobemstomig + nab-paclitaxel versus pembrolizumab + nab-paclitaxel in previously untreated PD-L1-positive advanced triple-negative breast cancer
NL-OMON58780Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of tobemstomig in triple-negative breast cancer (TNBC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Jun 2024; status: completed.
02
Drugs
tobemstomig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NL-OMON58780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58780.